文献速递毛发、甲与色素性疾病

deuruxolitinib治疗成人斑秃的3期THRIVE-AA1试验

Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1).
PubMed 文献 · J Am Acad Dermatol · 2024-07-23

THRIVE-AA1为3期随机双盲安慰剂对照试验,纳入18-65岁、脱发≥50%的成人斑秃患者,随机接受deuruxolitinib 8 mg每日两次、12 mg每日两次或安慰剂治疗24周。达到SALT评分≤20的主要终点比例分别为8 mg组29.6%、12 mg组41.5%、安慰剂组0.8%;两剂量组在所有次要终点上均显著优于安慰剂,患者满意度与毛发再生一致。

要点

  • deuruxolitinib 8 mg与12 mg每日两次治疗24周,毛发再生主要终点均显著优于安慰剂。
  • SALT≤20达标率:8 mg组29.6%、12 mg组41.5%、安慰剂组0.8%。
  • 多数治疗中出现的不良事件为轻中度,与其他口服JAK抑制剂一致。

核心结论

  • deuruxolitinib两种剂量对斑秃毛发再生均有效,患者满意度与毛发再生一致。

研究设计与样本

  • 3期随机双盲安慰剂对照试验THRIVE-AA1(NCT04518995)。
  • 纳入18-65岁、脱发≥50%的成人斑秃患者。
  • 随机接受deuruxolitinib 8 mg每日两次、12 mg每日两次或安慰剂治疗24周。

主要发现

  • 达到主要终点SALT评分≤20的比例:8 mg组29.6%、12 mg组41.5%、安慰剂组0.8%。
  • 毛发患者报告结局满意度应答者比例:8 mg组42.1%、12 mg组53.0%、安慰剂组4.7%。
  • 两剂量组在所有次要终点上均较安慰剂显著改善。
  • 多数治疗中出现的不良事件为轻或中度,与其他口服JAK抑制剂一致。

关键数值与推荐

  • 主要终点为达到SALT评分≤20的患者百分比。
  • 关键次要终点为毛发患者报告结局满意度应答者百分比。

临床怎么用

  • 对于脱发≥50%的成人斑秃患者,可考虑口服deuruxolitinib 8 mg或12 mg每日两次以促进毛发再生。
  • 治疗决策需结合患者满意度与安全性评估。

局限性

  • 需进一步研究了解长期安全性、疗效及停药影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Alopecia areata (AA) is a hair loss disorder that can seriously impact quality of life. Janus kinase (JAK) inhibitors, including deuruxolitinib, have previously demonstrated significant hair regrowth in AA. OBJECTIVE: The Phase 3 THRIVE-AA1 randomized, double-blinded, placebo-controlled trial (NCT04518995) evaluated the safety and efficacy of the oral JAK1/JAK2 inhibitor deuruxolitinib in adult patients with AA. METHODS: Patients aged 18-65 years with ≥50% hair loss were randomized to deuruxolitinib 8 mg twice daily, deuruxolitinib 12 mg twice daily, or placebo for 24 weeks. The primary end point was the percentage of patients achieving a Severity of Alopecia Tool score ≤20. A key secondary end point was the percentage of satisfaction of hair patient-reported outcome responders. RESULTS: Significantly higher proportions of patients taking deuruxolitinib met the primary end point (8 mg 29.6%; 12 mg 41.5% versus placebo 0.8%). Both deuruxolitinib doses achieved significant improvements in all secondary end points versus placebo, including satisfaction of hair patient-reported outcome (8 mg 42.1%; 12 mg 53.0% versus placebo 4.7%). Most treatment-emergent adverse events were mild or moderate, consistent with other oral JAK inhibitors. LIMITATIONS: Further studies are required to understand longer-term safety, efficacy, and impact of treatment cessation. CONCLUSION: Both doses of deuruxolitinib were effective for hair regrowth. Patient satisfaction aligned with hair growth.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. King B, Senna MM, Mesinkovska NA, et al. Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1). J Am Acad Dermatol. 2024. PMID: 39053611. doi:10.1016/j.jaad.2024.06.097

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。